A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation studyJesse J. Swen, Roelof Bosch, Cathelijne H. van der Wouden et al.|The Lancet|2023Cited by 508
Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working GroupClare Turnbull, Chaitanya Bandlamudi, Preethi Srinivasan et al.|Annals of Oncology|2019Cited by 237